Reference
Zhao N, et al. Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report. Medicine 101: No. 49, et al. Dec 2022. Available from: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750594/pdf/medi-101-e31875.pdf
Rights and permissions
About this article
Cite this article
Afatinib. Reactions Weekly 1939, 24 (2023). https://doi.org/10.1007/s40278-023-31432-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-31432-z